The GPRIN1 Knockout A-549 Polyclonal Cells are a ready-to-use, CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. This product provides a genetically heterogeneous pool of cells carrying targeted GPRIN1 gene disruption, facilitating loss-of-function analyses while minimizing clonal selection biases. The knockout is achieved by transient Cas9 and guide RNA expression, yielding a diverse edited allele repertoire ideal for population-based signaling and phenotypic studies.
The A-549 cell line originates from human lung adenocarcinoma and serves as a widely used alveolar basal epithelial model. Characterized by robust adherent growth and retention of type II pneumocyte features, it is instrumental in cancer research for studying oncogenic signaling, drug resistance, and cell migration. Its genetic and phenotypic stability makes it a reliable host for gene perturbation studies, and the GPRIN1 knockout in this background provides a clinically pertinent system to investigate lung adenocarcinoma biology.
GPRIN1 functions as a downstream effector of G??i/o proteins, bridging GPCR activation to cytoskeletal reorganization. It interacts with GNAI2 and GNAO1 and associates with YWHAZ, modulating its activity. Upon receptor stimulation, GPRIN1 promotes Rac1 and Cdc42 activation, leading to PAK-mediated actin remodeling, and also influences MAPK/ERK signaling. This positions GPRIN1 as a key integrator of signals from G??i/o-coupled receptors activated by neurotrophic factors and mitogens, regulating cell shape, migration, and proliferation.
Knockout of GPRIN1 in A-549 cells enables detailed investigation of its role in lung adenocarcinoma motility and growth. A-549 cells?? inherent migratory capacity and expression of diverse GPCRs make this model particularly suited for dissecting GPRIN1-dependent Rac1/Cdc42 and ERK1/2 pathway contributions. By disrupting GPRIN1, researchers can test its involvement in transducing promigratory and proliferative signals from the microenvironment, clarifying its potential as a therapeutic vulnerability in adenocarcinoma.
The polyclonal knockout cells are applicable to Transwell migration, wound-healing, and proliferation assays, as well as immunofluorescence for actin cytoskeleton analysis. Molecular profiling using RNA-seq, RT-qPCR, and western blot can reveal pathway alterations, while co-immunoprecipitation explores interactions with GNAI2 and YWHAZ. This product supports drug target validation and mechanistic studies of G??i/o-coupled receptor signaling in cancer. For lot-specific quality data and technical support, contact Ascent Research.
